009290 — Kwangdong Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩231bn
- KR₩373bn
- KR₩2tn
- 65
- 79
- 67
- 83
Annual income statement for Kwangdong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,243,770 | 1,338,182 | 1,431,545 | 1,514,454 | 1,640,719 |
| Cost of Revenue | |||||
| Gross Profit | 257,709 | 274,253 | 282,048 | 299,827 | 299,298 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,199,914 | 1,293,246 | 1,393,198 | 1,474,925 | 1,612,865 |
| Operating Profit | 43,856 | 44,936 | 38,347 | 39,529 | 27,854 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 62,951 | 34,329 | 36,291 | 49,019 | 57,325 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 45,602 | 25,541 | 26,701 | 39,372 | 41,845 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 45,370 | 24,019 | 24,174 | 36,966 | 40,481 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 45,370 | 24,032 | 24,174 | 36,966 | 40,481 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1,148 | 583 | 584 | 1,003 | 997 |
| Dividends per Share |